Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling
- PMID: 19252332
- DOI: 10.2133/dmpk.24.3
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling
Abstract
Pharmacokinetic-Pharmacodynamic (PK-PD) modeling helps to better understand drug efficacy and safety and has, therefore, become a powerful tool in the learning-confirming cycles of drug-development. In translational drug research, mechanism-based PK-PD modeling has been recognized as a tool for bringing forward early insights in drug efficacy and safety into the clinical development. These models differ from descriptive PK-PD models in that they quantitatively characterize specific processes in the causal chain between drug administration and effect. This includes target site distribution, binding and activation, pharmacodynamic interactions, transduction and homeostatic feedback mechanisms. Compared to descriptive models mechanism-based PK-PD models that utilize receptor theory concepts for characterization of target binding and target activation processes have improved properties for extrapolation and prediction. In this respect, receptor theory constitutes the basis for 1) prediction of in vivo drug concentration-effect relationships and 2) characterization of target association-dissociation kinetics as determinants of hysteresis in the time course of the drug effect. This approach intrinsically distinguishes drug- and system specific parameters explicitly, allowing accurate extrapolation from in vitro to in vivo and across species. This review provides an overview of recent developments in incorporating receptor theory in PK-PD modeling with a specific focus on the identifiability of these models.
Similar articles
-
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.Annu Rev Pharmacol Toxicol. 2007;47:357-400. doi: 10.1146/annurev.pharmtox.47.120505.105154. Annu Rev Pharmacol Toxicol. 2007. PMID: 17067280 Review.
-
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.Trends Pharmacol Sci. 2008 Apr;29(4):186-91. doi: 10.1016/j.tips.2008.01.007. Epub 2008 Mar 18. Trends Pharmacol Sci. 2008. PMID: 18353445 Review.
-
Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.Pharm Res. 2005 Sep;22(9):1432-7. doi: 10.1007/s11095-005-5882-3. Epub 2005 Aug 24. Pharm Res. 2005. PMID: 16132354
-
Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.J Pharmacol Toxicol Methods. 2014 Jul-Aug;70(1):73-85. doi: 10.1016/j.vascn.2014.05.004. Epub 2014 May 28. J Pharmacol Toxicol Methods. 2014. PMID: 24879942
-
Scaling pharmacodynamics from in vitro and preclinical animal studies to humans.Drug Metab Pharmacokinet. 2009;24(1):16-24. doi: 10.2133/dmpk.24.16. Drug Metab Pharmacokinet. 2009. PMID: 19252333 Free PMC article. Review.
Cited by
-
PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats.Br J Pharmacol. 2013 Aug;169(7):1510-24. doi: 10.1111/bph.12190. Br J Pharmacol. 2013. PMID: 23849040 Free PMC article.
-
Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetine.Br J Pharmacol. 2010 May;160(2):389-98. doi: 10.1111/j.1476-5381.2010.00719.x. Br J Pharmacol. 2010. PMID: 20423348 Free PMC article.
-
Molecular mechanism matters: Benefits of mechanistic computational models for drug development.Pharmacol Res. 2015 Sep;99:149-54. doi: 10.1016/j.phrs.2015.06.002. Epub 2015 Jun 18. Pharmacol Res. 2015. PMID: 26093283 Free PMC article. Review.
-
Inhibition of snowshoe hare succinate dehydrogenase activity as a mechanism of deterrence for papyriferic acid in birch.J Chem Ecol. 2011 Dec;37(12):1285-93. doi: 10.1007/s10886-011-0039-9. Epub 2011 Nov 25. J Chem Ecol. 2011. PMID: 22116690
-
Parameter Identifiability of Fundamental Pharmacodynamic Models.Front Physiol. 2016 Dec 5;7:590. doi: 10.3389/fphys.2016.00590. eCollection 2016. Front Physiol. 2016. PMID: 27994553 Free PMC article.